NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.